메뉴 건너뛰기




Volumn 29, Issue 6, 2015, Pages 721-731

Erratum: Defining response to anti-VEGF therapies in neovascular AMD (Eye (Basingstoke) (2015) 29 (721-731) DOI: 10.1038/eye.2015.48);Defining response to anti-VEGF therapies in neovascular AMD

(16)  Amoaku, W M a   Chakravarthy, U b   Gale, R c   Gavin, M d   Ghanchi, F e   Gibson, J f   Harding, S g   Johnston, R L h   Kelly, S i   Lotery, A j   Mahmood, S k   Menon, G l   Sivaprasad, S m   Talks, J n   Tufail, A o   Yang, Y p  


Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

EID: 84930846232     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2015.159     Document Type: Erratum
Times cited : (229)

References (77)
  • 1
    • 84856002562 scopus 로고    scopus 로고
    • Incidence of legal blindness from age-related macular degeneration in Denmark: Year 2000 to 2010
    • Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012; 153: 209-213.
    • (2012) Am J Ophthalmol , vol.153 , pp. 209-213
    • Bloch, S.B.1    Larsen, M.2    Munch, I.C.3
  • 3
    • 84863882859 scopus 로고    scopus 로고
    • Visual impairment certification secondary to ARMD in Leeds, 2005-2010: Is the incidence falling?
    • Rostron E, McKibbin M. Visual impairment certification secondary to ARMD in Leeds, 2005-2010: is the incidence falling? Eye (Lond) 2012; 26: 933-936.
    • (2012) Eye (Lond) , vol.26 , pp. 933-936
    • Rostron, E.1    McKibbin, M.2
  • 4
    • 84882242958 scopus 로고    scopus 로고
    • Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK
    • Keenan TD, Kelly SP, Sallam A, Mohamed Q, Tufail A, Johnston RL et al. Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK. Br J Ophthalmol 2013; 97: 1168-1172.
    • (2013) Br J Ophthalmol , vol.97 , pp. 1168-1172
    • Keenan, T.D.1    Kelly, S.P.2    Sallam, A.3    Mohamed, Q.4    Tufail, A.5    Johnston, R.L.6
  • 5
    • 84887150456 scopus 로고    scopus 로고
    • Seven-year outcomes in ranibizumab-treated patients in ANCHOR MARINA and HORIZON: A multicenter cohort study (SEVEN-UP)
    • Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013; 120: 2292-2299.
    • (2013) Ophthalmology , vol.120 , pp. 2292-2299
    • Rofagha, S.1    Bhisitkul, R.B.2    Boyer, D.S.3    Sadda, S.R.4    Zhang, K.5
  • 6
    • 84888005046 scopus 로고    scopus 로고
    • A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration
    • Rasmussen A, Bloch SB, Fuchs J, Hansen LH, Larsen M, Lacour M et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 2013; 120: 2630-2636.
    • (2013) Ophthalmology , vol.120 , pp. 2630-2636
    • Rasmussen, A.1    Bloch, S.B.2    Fuchs, J.3    Hansen, L.H.4    Larsen, M.5    Lacour, M.6
  • 7
    • 70450201592 scopus 로고    scopus 로고
    • Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment
    • Amoaku W. Ranibizumab: the clinician's guide to commencing, continuing, and discontinuing treatment. Eye 2009; 23: 2140-2142.
    • (2009) Eye , vol.23 , pp. 2140-2142
    • Amoaku, W.1
  • 8
    • 84984932434 scopus 로고    scopus 로고
    • The royal college of ophthalmologists guidelines on AMD: Executive summary
    • Chakravarthy U, Williams M. The AMD Guidelines Group. The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary. Eye 2013; 27: 1429-1431.
    • (2013) Eye , vol.27 , pp. 1429-1431
    • Chakravarthy, U.1    Williams, M.2
  • 10
    • 79955615679 scopus 로고    scopus 로고
    • Retreatment criteria in anti-VEGF therapy of exudative AMD: Critical analysis of present regimes and new morphological definition of "lesion activity"
    • Pauliekhoff D, Kirchhof B. Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity". Graefes Arch Clin Exp Ophthalmol 2011; 249: 631-632.
    • (2011) Graefes Arch Clin Exp Ophthalmol , vol.249 , pp. 631-632
    • Pauliekhoff, D.1    Kirchhof, B.2
  • 11
    • 84865721295 scopus 로고    scopus 로고
    • EVEREST study: Efficacy and safety of verteporfin PDT in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy
    • Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H et al. EVEREST study: efficacy and safety of verteporfin PDT in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; 32: 1453-1464.
    • (2012) Retina , vol.32 , pp. 1453-1464
    • Koh, A.1    Lee, W.K.2    Chen, L.J.3    Chen, S.J.4    Hashad, Y.5    Kim, H.6
  • 12
    • 84875933604 scopus 로고    scopus 로고
    • Expert PCV Panel. Polypoidal choroidal vasculopathy: Evidence-based guidelines for clinical diagnosis and treatment
    • Koh AH, Chen LJ, Chen SJ, Chen Y, Giridhar A et al. Expert PCV Panel. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 2013; 33: 686-716.
    • (2013) Retina , vol.33 , pp. 686-716
    • Koh, A.H.1    Chen, L.J.2    Chen, S.J.3    Chen, Y.4    Giridhar, A.5
  • 13
    • 84856134918 scopus 로고    scopus 로고
    • The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: The Lucentis Genotype Study (An American Ophthalmological Society Thesis)
    • Francis PJ. The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: The Lucentis Genotype Study (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc 2011; 109: 115-156.
    • (2011) Trans Am Ophthalmol Soc , vol.109 , pp. 115-156
    • Francis, P.J.1
  • 14
    • 84883806471 scopus 로고    scopus 로고
    • Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials
    • Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS et al. For The CATT Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013; 120: 1860-1870.
    • (2013) Ophthalmology , vol.120 , pp. 1860-1870
    • Jaffe, G.J.1    Martin, D.F.2    Toth, C.A.3    Daniel, E.4    Maguire, M.G.5    Ying, G.S.6
  • 15
    • 84885448955 scopus 로고    scopus 로고
    • A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration
    • Kitchens JW, Kassem N, Wood W, Stone TW, Isernhagen R, Wood E et al. A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. Clin Ophthalmol 2013; 7: 1987-1993.
    • (2013) Clin Ophthalmol , vol.7 , pp. 1987-1993
    • Kitchens, J.W.1    Kassem, N.2    Wood, W.3    Stone, T.W.4    Isernhagen, R.5    Wood, E.6
  • 16
    • 84899934956 scopus 로고    scopus 로고
    • Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group the neovascular age-related macular degeneration database: Multicenter study of 92 976 ranibizumab injections. Teport 1: Visual acuity
    • Tufail A, Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T et al. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections. teport 1: visual acuity. Ophthalmology 2014; 121: 1092-1101.
    • (2014) Ophthalmology , vol.121 , pp. 1092-1101
    • Tufail, A.1    Zarranz-Ventura, J.2    Liew, G.3    Johnston, R.L.4    Xing, W.5    Akerele, T.6
  • 17
    • 84908149389 scopus 로고    scopus 로고
    • The neovascular age-related macular degeneration database: Report 2. Incidence, management and visual outcomes of second treated eyes
    • Zarranz-Ventura J, Liew G, Johnston R, Tufail A, Xing W, Akerele T et al. The neovascular age-related macular degeneration database: report 2. Incidence, management and visual outcomes of second treated eyes. Ophthalmology 2014; 121: 1966-1975.
    • (2014) Ophthalmology , vol.121 , pp. 1966-1975
    • Zarranz-Ventura, J.1    Liew, G.2    Johnston, R.3    Tufail, A.4    Xing, W.5    Akerele, T.6
  • 19
    • 83455255286 scopus 로고    scopus 로고
    • Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12
    • Williams TA, Blyth CP. Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. Eye 2011; 25: 1617-1621.
    • (2011) Eye , vol.25 , pp. 1617-1621
    • Williams, T.A.1    Blyth, C.P.2
  • 20
    • 84859110467 scopus 로고    scopus 로고
    • Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration
    • Lim JH, Wickremasinghe SS, Xie J, Chauhan DS, Baird PN, Robman LD et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol 2012; 153: 678-686.
    • (2012) Am J Ophthalmol , vol.153 , pp. 678-686
    • Lim, J.H.1    Wickremasinghe, S.S.2    Xie, J.3    Chauhan, D.S.4    Baird, P.N.5    Robman, L.D.6
  • 21
    • 84872026174 scopus 로고    scopus 로고
    • Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration
    • Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C et al. CATT Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013; 120: 122-129.
    • (2013) Ophthalmology , vol.120 , pp. 122-129
    • Ying, G.S.1    Huang, J.2    Maguire, M.G.3    Jaffe, G.J.4    Grunwald, J.E.5    Toth, C.6
  • 23
    • 33749451356 scopus 로고    scopus 로고
    • Ranibizumab versus verteporfin for neovascular age-related macular degeneration
    • Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
    • (2006) N Engl J Med , vol.355 , pp. 1432-1444
    • Brown, D.M.1    Kaiser, P.K.2    Michels, M.3    Soubrane, G.4    Heier, J.S.5    Kim, R.Y.6
  • 24
    • 57949094834 scopus 로고    scopus 로고
    • Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
    • Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.
    • (2009) Ophthalmology , vol.116 , pp. 57-65
    • Brown, D.M.1    Michels, M.2    Kaiser, P.K.3    Heier, J.S.4    Sy, J.P.5    Ianchulev, T.6
  • 26
    • 75749133304 scopus 로고    scopus 로고
    • The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: Outcomes of a drug and disease model
    • Holz FG, Korobelnick JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S et al. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 2010; 51: 405-412.
    • (2010) Invest Ophthalmol Vis Sci , vol.51 , pp. 405-412
    • Holz, F.G.1    Korobelnick, J.F.2    Lanzetta, P.3    Mitchell, P.4    Schmidt-Erfurth, U.5    Wolf, S.6
  • 27
    • 79953295148 scopus 로고    scopus 로고
    • SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study
    • Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO et al. SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118: 663-671.
    • (2011) Ophthalmology , vol.118 , pp. 663-671
    • Holz, F.G.1    Amoaku, W.2    Donate, J.3    Guymer, R.H.4    Kellner, U.5    Schlingemann, R.O.6
  • 28
    • 78049279239 scopus 로고    scopus 로고
    • Treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact
    • Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD et al. Treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010; 117: 2134-2140.
    • (2010) Ophthalmology , vol.117 , pp. 2134-2140
    • Gupta, O.P.1    Shienbaum, G.2    Patel, A.H.3    Fecarotta, C.4    Kaiser, R.S.5    Regillo, C.D.6
  • 29
    • 84857446008 scopus 로고    scopus 로고
    • Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: Clinical and economic impact
    • Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD et al. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol. 2012; 153: e1.
    • (2012) Am J Ophthalmol. , vol.153 , pp. e1
    • Shienbaum, G.1    Gupta, O.P.2    Fecarotta, C.3    Patel, A.H.4    Kaiser, R.S.5    Regillo, C.D.6
  • 30
    • 85017808888 scopus 로고    scopus 로고
    • Early vs delayed 15-Letter responders to ranibizumab treatment in year 1 of the Phase III HARBOR Trial
    • Dreyer R, Kokame GT, Stoller G et al. Early vs delayed 15-Letter responders to ranibizumab treatment in year 1 of the Phase III HARBOR Trial. Invest Ophthalmol Vis Sci 2013; 54: 3829.
    • (2013) Invest Ophthalmol Vis Sci , vol.54 , pp. 3829
    • Dreyer, R.1    Kokame, G.T.2    Stoller, G.3
  • 31
    • 84888610071 scopus 로고    scopus 로고
    • Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration
    • Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S et al. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol 2013; 97: 1443-1446.
    • (2013) Br J Ophthalmol , vol.97 , pp. 1443-1446
    • Krebs, I.1    Glittenberg, C.2    Ansari-Shahrezaei, S.3    Hagen, S.4    Steiner, I.5    Binder, S.6
  • 32
    • 38349172455 scopus 로고    scopus 로고
    • Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1
    • Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145: 239-248.
    • (2008) Am J Ophthalmol , vol.145 , pp. 239-248
    • Regillo, C.D.1    Brown, D.M.2    Abraham, P.3    Yue, H.4    Ianchulev, T.5    Schneider, S.6
  • 33
    • 79955631484 scopus 로고    scopus 로고
    • EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study
    • Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R et al. EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011; 118: 831-839.
    • (2011) Ophthalmology , vol.118 , pp. 831-839
    • Schmidt-Erfurth, U.1    Eldem, B.2    Guymer, R.3    Korobelnik, J.F.4    Schlingemann, R.O.5    Axer-Siegel, R.6
  • 34
    • 84873867315 scopus 로고    scopus 로고
    • Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration
    • Hariprasad SM, Morse LS, Shapiro H, Wong P, Tuomi L. Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration. J Ophthalmol 2012; 2012: 690641.
    • (2012) J Ophthalmol , vol.2012 , pp. 690641
    • Hariprasad, S.M.1    Morse, L.S.2    Shapiro, H.3    Wong, P.4    Tuomi, L.5
  • 35
    • 85027955048 scopus 로고    scopus 로고
    • Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)
    • Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012; 32: 434-457.
    • (2012) Retina , vol.32 , pp. 434-457
    • Stewart, M.W.1    Rosenfeld, P.J.2    Penha, F.M.3    Wang, F.4    Yehoshua, Z.5    Bueno-Lopez, E.6
  • 36
    • 84873325259 scopus 로고    scopus 로고
    • Super-dose Anti-VEGF (SAVE): Trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point
    • Brown DM, Chen E, Mariani A, Major JC. Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology 2013; 120: 349-354.
    • (2013) Ophthalmology , vol.120 , pp. 349-354
    • Brown, D.M.1    Chen, E.2    Mariani, A.3    Major, J.C.4
  • 37
    • 84875209738 scopus 로고    scopus 로고
    • For the CATT Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)
    • Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG et al. For The CATT Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2013; 120: 593-599.
    • (2013) Ophthalmology , vol.120 , pp. 593-599
    • Hagstrom, S.A.1    Ying, G.S.2    Pauer, G.J.3    Sturgill-Short, G.M.4    Huang, J.5    Callanan, D.G.6
  • 38
    • 84887989386 scopus 로고    scopus 로고
    • For the IVAN Study Group. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study
    • Lotery AJ, Gibson J, Cree AJ, Downes SM, Harding SP, Rogers CA et al. For The IVAN Study Group. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study. Ophthalmology 2013; 120: 2637-2643.
    • (2013) Ophthalmology , vol.120 , pp. 2637-2643
    • Lotery, A.J.1    Gibson, J.2    Cree, A.J.3    Downes, S.M.4    Harding, S.P.5    Rogers, C.A.6
  • 40
    • 78649936436 scopus 로고    scopus 로고
    • Clinical risk factors for age-related macular degeneration: A systematic review and meta-analysis
    • Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010; 10: 31.
    • (2010) BMC Ophthalmol , vol.10 , pp. 31
    • Chakravarthy, U.1    Wong, T.Y.2    Fletcher, A.3    Piault, E.4    Evans, C.5    Zlateva, G.6
  • 41
    • 0031657921 scopus 로고    scopus 로고
    • Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat
    • Shen WY, Yu MJ, Barry CJ, Constable IJ, Rakoczy PE et al. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat. Br J Ophthalmol 1998; 82: 1063-1071.
    • (1998) Br J Ophthalmol , vol.82 , pp. 1063-1071
    • Shen, W.Y.1    Yu, M.J.2    Barry, C.J.3    Constable, I.J.4    Rakoczy, P.E.5
  • 42
    • 0029758823 scopus 로고    scopus 로고
    • Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes
    • Frank RN, Amin RH, Eliot D, Puklin JE, Abrams GW et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996; 122: 393-403.
    • (1996) Am J Ophthalmol , vol.122 , pp. 393-403
    • Frank, R.N.1    Amin, R.H.2    Eliot, D.3    Puklin, J.E.4    Abrams, G.W.5
  • 43
    • 0005581823 scopus 로고    scopus 로고
    • Growth factors in age-related macular degeneration: Pathogenic and therapeutic implications
    • Frank RN. Growth factors in age-related macular degeneration: Pathogenic and therapeutic implications. Ophthalmic Res 1997; 31: 243-244.
    • (1997) Ophthalmic Res , vol.31 , pp. 243-244
    • Frank, R.N.1
  • 44
    • 81555214460 scopus 로고    scopus 로고
    • Cytokines in neovascular age-related macular degeneration: Fundamentals of targeted combination therapy
    • Dias JR, Rodrigues EB, Maia M, Magalhães Jr O, Penha FM, Farah ME et al. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol 2011; 95: 1631-1637.
    • (2011) Br J Ophthalmol , vol.95 , pp. 1631-1637
    • Dias, J.R.1    Rodrigues, E.B.2    Maia, M.3    Magalhães, Jr.O.4    Penha, F.M.5    Farah, M.E.6
  • 45
    • 56549111386 scopus 로고    scopus 로고
    • Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?
    • Schaal S, Kaplan JG, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008; 115: 2199-2205.
    • (2008) Ophthalmology , vol.115 , pp. 2199-2205
    • Schaal, S.1    Kaplan, J.G.2    Tezel, T.H.3
  • 46
    • 58149190795 scopus 로고    scopus 로고
    • Pathways mediating resistance to vascular endothelial growth factor-targeted therapy
    • Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008; 14: 6371-6375.
    • (2008) Clin Cancer Res , vol.14 , pp. 6371-6375
    • Ellis, L.M.1    Hicklin, D.J.2
  • 47
    • 26644471951 scopus 로고    scopus 로고
    • Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late-stage pancreatic islet tumors
    • Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
    • (2005) Cancer Cell , vol.8 , pp. 299-309
    • Casanovas, O.1    Hicklin, D.J.2    Bergers, G.3    Hanahan, D.4
  • 48
    • 33846149645 scopus 로고    scopus 로고
    • AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalises tumor vasculature and alleviates edema in glioblastoma patients
    • Batchelor TT, Sorenson AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalises tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
    • (2007) Cancer Cell , vol.11 , pp. 83-95
    • Batchelor, T.T.1    Sorenson, A.G.2    Di Tomaso, E.3    Zhang, W.T.4    Duda, D.G.5    Cohen, K.S.6
  • 49
    • 84867493598 scopus 로고    scopus 로고
    • Pilot study to evaLuate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrent macular fluid o30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study)
    • Fung AT, Kumar N, Vance SK, Slakter JS, Klancnik JM, Spaide RS et al. Pilot study to evaLuate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrent macular fluid o30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye 2012; 26: 1181-1187.
    • (2012) Eye , vol.26 , pp. 1181-1187
    • Fung, A.T.1    Kumar, N.2    Vance, S.K.3    Slakter, J.S.4    Klancnik, J.M.5    Spaide, R.S.6
  • 50
    • 0000658715 scopus 로고    scopus 로고
    • Neurotransmission: The autonomic and somatic motor nervous systems
    • Goodman LS, Hardman JG, Limbird LE et al. (eds). 10th edn. McGraw-Hill: New York, NY, USA
    • Hoffman BB, Taylor P. Neurotransmission: the autonomic and somatic motor nervous systems. In: Goodman LS, Hardman JG, Limbird LE et al. (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn. McGraw-Hill: New York, NY, USA, 2001; 115-154.
    • (2001) Goodman and Gilman's the Pharmacological Basis of Therapeutics , pp. 115-154
    • Hoffman, B.B.1    Taylor, P.2
  • 51
    • 33645061248 scopus 로고    scopus 로고
    • Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients
    • Tsagaraki V, Amfilochiou A, Markantonis SL. Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients. Int J Clin Pract 2006; 60: 415-421.
    • (2006) Int J Clin Pract , vol.60 , pp. 415-421
    • Tsagaraki, V.1    Amfilochiou, A.2    Markantonis, S.L.3
  • 52
    • 3042781690 scopus 로고    scopus 로고
    • The effect of daily use of brimonidine tartrate on the dark-adapted pupil diameter
    • Brown SM, Khanani AM, McCartney DL. The effect of daily use of brimonidine tartrate on the dark-adapted pupil diameter. Am J Ophthalmol 2004; 138: 149-151.
    • (2004) Am J Ophthalmol , vol.138 , pp. 149-151
    • Brown, S.M.1    Khanani, A.M.2    McCartney, D.L.3
  • 53
    • 36448985258 scopus 로고    scopus 로고
    • Monitoring patients treated with anti-TNFalpha biopharmaceuticals: Assessing serum infliximab and anti-infliximab antibodies
    • Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNFalpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007; 46: 1828-1834.
    • (2007) Rheumatology , vol.46 , pp. 1828-1834
    • Svenson, M.1    Geborek, P.2    Saxne, T.3    Bendtzen, K.4
  • 54
    • 48249144751 scopus 로고    scopus 로고
    • Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration
    • Keane PA, Liakopoulos S, Ongchin SC, Heussen FM, Msutta S, Chang KT et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49: 3115-3120.
    • (2008) Invest Ophthalmol Vis Sci , vol.49 , pp. 3115-3120
    • Keane, P.A.1    Liakopoulos, S.2    Ongchin, S.C.3    Heussen, F.M.4    Msutta, S.5    Chang, K.T.6
  • 55
    • 65349118184 scopus 로고    scopus 로고
    • Bevacizumab tachyphylaxis
    • author reply 1017
    • Falavarjani KG, Modarres M. Bevacizumab tachyphylaxis. Ophthalmology 2009; 116: 1016-1017 author reply 1017.
    • (2009) Ophthalmology , vol.116 , pp. 1016-1017
    • Falavarjani, K.G.1    Modarres, M.2
  • 56
    • 67749106387 scopus 로고    scopus 로고
    • Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration
    • Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 2009; 29: 723-731.
    • (2009) Retina , vol.29 , pp. 723-731
    • Forooghian, F.1    Cukras, C.2    Meyerle, C.B.3    Chew, E.Y.4    Wong, W.T.5
  • 58
    • 80052547257 scopus 로고    scopus 로고
    • Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab
    • Almony A, Mansouri A, Shah GK, Blinder KJ. Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab. Can J Ophthalmol 2011; 46: 182-185.
    • (2011) Can J Ophthalmol , vol.46 , pp. 182-185
    • Almony, A.1    Mansouri, A.2    Shah, G.K.3    Blinder, K.J.4
  • 59
  • 60
    • 84455204035 scopus 로고    scopus 로고
    • Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab
    • Eghoj MS, Sorenson TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2012; 96: 21-23.
    • (2012) Br J Ophthalmol , vol.96 , pp. 21-23
    • Eghoj, M.S.1    Sorenson, T.L.2
  • 61
    • 84879235232 scopus 로고    scopus 로고
    • Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
    • Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013; 156: 15-22.
    • (2013) Am J Ophthalmol , vol.156 , pp. 15-22
    • Bakall, B.1    Folk, J.C.2    Boldt, H.C.3    Sohn, E.H.4    Stone, E.M.5    Russell, S.R.6
  • 62
    • 84880005310 scopus 로고    scopus 로고
    • Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
    • Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013; 97: 1032-1035.
    • (2013) Br J Ophthalmol , vol.97 , pp. 1032-1035
    • Cho, H.1    Shah, C.P.2    Weber, M.3    Heier, J.S.4
  • 63
    • 84879203732 scopus 로고    scopus 로고
    • Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration
    • Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 2013; 156: 29-35.
    • (2013) Am J Ophthalmol , vol.156 , pp. 29-35
    • Yonekawa, Y.1    Andreoli, C.2    Miller, J.B.3    Loewenstein, J.I.4    Sobrin, L.5    Eliott, D.6
  • 64
    • 84883740682 scopus 로고    scopus 로고
    • Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration
    • Kumar N, Mansouri A, Shah GK, Fung AT, Slakter J, Sorenson J et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013; 33: 1605-1612.
    • (2013) Retina , vol.33 , pp. 1605-1612
    • Kumar, N.1    Mansouri, A.2    Shah, G.K.3    Fung, A.T.4    Slakter, J.5    Sorenson, J.6
  • 65
    • 84922391789 scopus 로고    scopus 로고
    • Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD
    • Ehlken C, Jungmann S, Bohringer D, Agostini HT, Junker B, Pielen A et al. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye 2014; 28: 538-545.
    • (2014) Eye , vol.28 , pp. 538-545
    • Ehlken, C.1    Jungmann, S.2    Bohringer, D.3    Agostini, H.T.4    Junker, B.5    Pielen, A.6
  • 66
    • 79958748965 scopus 로고    scopus 로고
    • A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications
    • Kelly SP, Barua A. A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications. Eye (Lond) 2011; 25: 710-716.
    • (2011) Eye (Lond) , vol.25 , pp. 710-716
    • Kelly, S.P.1    Barua, A.2
  • 67
    • 21744461121 scopus 로고    scopus 로고
    • Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration
    • Oliver-Fernandez A, Bakal J, Segal S, Shah GK, Dugar A, Sharma S et al. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol 2005; 40: 313-319.
    • (2005) Can J Ophthalmol , vol.40 , pp. 313-319
    • Oliver-Fernandez, A.1    Bakal, J.2    Segal, S.3    Shah, G.K.4    Dugar, A.5    Sharma, S.6
  • 68
    • 60149107965 scopus 로고    scopus 로고
    • Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss
    • Arias L, Armadá F, Donate J, García-Arumí J, Giralt J, Pazos B et al. Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye 2009; 23: 326-333.
    • (2009) Eye , vol.23 , pp. 326-333
    • Arias, L.1    Armadá, F.2    Donate, J.3    García-Arumí, J.4    Giralt, J.5    Pazos, B.6
  • 69
    • 79952993616 scopus 로고    scopus 로고
    • Early treatment of exudative age-related macular degeneration with ranibizumab (Lucentis): The key to success
    • Matthe E, Sandner D. Early treatment of exudative age-related macular degeneration with ranibizumab (Lucentis): the key to success. Ophthalmologe 2011; 108: 237-243.
    • (2011) Ophthalmologe , vol.108 , pp. 237-243
    • Matthe, E.1    Sandner, D.2
  • 70
    • 79955590384 scopus 로고    scopus 로고
    • Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity
    • Muether PS, Hermann MM, Koch K, Fauser S. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol 2011; 249: 633-637.
    • (2011) Graefes Arch Clin Exp Ophthalmol , vol.249 , pp. 633-637
    • Muether, P.S.1    Hermann, M.M.2    Koch, K.3    Fauser, S.4
  • 71
    • 36249002808 scopus 로고    scopus 로고
    • Ranibizumab for predominantly classic neovascular age-related macular degeneration: Subgroup analysis of first-year ANCHOR results
    • Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007; 144: 850-857.
    • (2007) Am J Ophthalmol , vol.144 , pp. 850-857
    • Kaiser, P.K.1    Brown, D.M.2    Zhang, K.3    Hudson, H.L.4    Holz, F.G.5    Shapiro, H.6
  • 74
    • 84891631034 scopus 로고    scopus 로고
    • Intravitreal Aflibercept injection for neovascular age-related macular degeneration: Ninety-Six-Week results of the VIEW Studies
    • Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V. Intravitreal Aflibercept injection for neovascular age-related macular degeneration: Ninety-Six-Week results of the VIEW Studies. Ophthalmology 2014; 121: 193-201.
    • (2014) Ophthalmology , vol.121 , pp. 193-201
    • Schmidt-Erfurth, U.1    Kaiser, P.K.2    Korobelnik, J.F.3    Brown, D.M.4    Chong, V.5
  • 75
    • 78651371501 scopus 로고    scopus 로고
    • Inject and extend dosing versus dosing as needed: A comparative retrospective study of ranibizumab in exudative age-related macular degeneration
    • Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011; 31: 26-30.
    • (2011) Retina , vol.31 , pp. 26-30
    • Oubraham, H.1    Cohen, S.Y.2    Samimi, S.3    Marotte, D.4    Bouzaher, I.5    Bonicel, P.6
  • 76
    • 84876971026 scopus 로고    scopus 로고
    • Current anti-vascular endothelial growth factor dosing regimens: Benefits and burden
    • Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology 2013; 120: S3-S7.
    • (2013) Ophthalmology , vol.120 , pp. S3-S7
    • Haller, J.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.